Press release
Anzor Pharmaceuticals Selected to Present at the Prestigious BioLabs-NYU Investor & Innovator Exchange
Anzor Pharmaceuticals is honored to announce its selection as a presenting company at the 2025 BioLabs-NYU Investor & Innovator Exchange, taking place on May 6, 2025, in New York City. This high-profile event, now in its second year, is co-hosted by BioLabs@NYULangone, NYU Langone Health, and NYU Technology Opportunities & Ventures, and brings together leading life sciences startups, investors, and industry strategics from across the nation.The Investor & Innovator Exchange is recognized as a premier platform for emerging biotech companies to showcase their innovations, connect with top-tier investors, and compete for opportunities such as fully funded lab space at BioLabs@NYULangone's state-of-the-art Manhattan facility. Anzor Pharmaceuticals' selection reflects the company's commitment to advancing breakthrough therapies and its growing reputation within the life sciences ecosystem.
"We are thrilled to be chosen to present at this year's BioLabs-NYU Investor & Innovator Exchange," said Chris Adams, CEO, of Anzor Pharmaceuticals. "This event is an exceptional opportunity to share our latest research on chronic kidney disease and drug pipeline with an audience of visionary investors and industry leaders, and to further our mission of delivering transformative therapies to patients in need."
The conference will feature pitch sessions, expert panels, and networking opportunities designed to foster collaboration and accelerate innovation in healthcare and biotechnology.
For more information about Anzor Pharmaceuticals, please visit www.anzorpharma.com.
Anzor Pharma
1660 Soldiers Field Rd
Boston, MA 01109
info@anzorpharma.com
About Anzor Pharmaceuticals
Anzor Pharmaceuticals is at the forefront of targeted fibroblast growth factor (FGF) therapies for cancer and metabolic disorders. The company's technology is based on proprietary FGF peptides and conjugates, with applications in obesity, chronic kidney disease, and skeletal disorders. Extensive research has demonstrated that FGF receptors are involved in several key pathways of disease
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anzor Pharmaceuticals Selected to Present at the Prestigious BioLabs-NYU Investor & Innovator Exchange here
News-ID: 4045673 • Views: β¦
More Releases for Pharma
Miglitol Market Size, Share and Forecast By Key Players-Weiao Pharma, Zhejiang M β¦
πππ, πππ° πππ«π¬ππ²- According to the MRI Team's Market Research Intellect, the global Miglitol market is anticipated to grow at a compound annual growth rate (CAGR) of 11.49% between 2024 and 2031. The market is expected to grow to USDΒ 22.32Β Billion by 2024. The valuation is expected to reach USDΒ 47.79Β Billion by 2031.
The Miglitol market is experiencing significant growth due to the rising prevalence of diabetes and the increasing awareness of theβ¦
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi β¦
πππ, πππ° πππ«π¬ππ²- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The Dacarbazine market is projected to witness significant growth in the coming years, driven by increasingβ¦
Dacarbazine Market Size, Share and Forecast By Key Players-Lingnan Pharma, Ruiyi β¦
πππ, πππ° πππ«π¬ππ²- According to the MRI Team's Market Research Intellect, the global Dacarbazine market is anticipated to grow at a compound annual growth rate (CAGR) of 14.63% between 2024 and 2031. The market is expected to grow to USD 25.32 Billion by 2024. The valuation is expected to reach USD 65.84 Billion by 2031.
The dacarbazine market is experiencing steady growth, driven by the rising incidence of cancer globally. Asβ¦
Epilepsy Pipeline Assessment 2024: Therapies, Clinical Trials, and Market Insigh β¦
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Epilepsy pipeline constitutes 75+ key companies continuously working towards developing 90+ Epilepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Epilepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of theβ¦
Global Indomethacin Market Seeking Excellent Growth by 2028 | Ratiopharm, Merck, β¦
"IBI has published a report entitled Global Indomethacin Market Research Report which provides comprehensive data on emerging trends, market drivers, growth opportunities, and barriers that could change the dynamics of the industry market. It provides an in-depth analysis of market segments which includes the product, application, and competitor analysis.
Click Here To Order A Sample Copy Of Indomethacin Global Market Report : https://www.infinitybusinessinsights.com/request_sample.php?id=380382
The Indomethacin Global Market Research Report provides close monitoringβ¦
Roxatidine Market 2020: Top Companies Analysis To Grow Healthcare Business by 20 β¦
Business Industry Reports Research has recently announced a report on Global Roxatidine Market based on the Category Industry. The Roxatidine Market report emphasizes various key aspects, which include growth drivers, restraints, opportunities and recent market trends for the forecast period 2020-2024.
Global Roxatidine Market overview:
Business Industry Reports Analyst covers the Major Players data, including: shipment, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about theβ¦
